Needham analyst Alex Henderson downgrades Viavi Solutions (NASDAQ:VIAV) from Buy to Hold.
HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Lowers Price Target to $200
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $210 to $200.